Skip to main content
. 2024 Feb 19;9(4):102384. doi: 10.1016/j.esmoop.2024.102384

Figure 2.

Figure 2

OS of all patients with NSCLC-LM and subgroup analysis. (A) The OS of all the patients. (B) Subgroup analysis for patients with and without brain parenchymal metastases. (C) Subgroup analysis for patients with good and bad ECOG scores. (D) Subgroup analysis for patients with and without clinical response for IP treatment. (E) With and without CSF cytological transformation to negative subgroup. (F) With and without neck pain, back pain, or defecation difficulty subgroup.

BM, brain parenchymal metastasis; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NBM, no brain parenchymal metastasis; OS, overall survival.